# OnCo record nct05950945 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05950945/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05950945", "NCT05950945" ;
  schema:name "Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer"@en ;
  schema:alternateName "DESTINY-Breast15"@en ;
  schema:description "A phase 3 trial of Trastuzumab deruxtecan in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, run by Daiichi Sankyo, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05950945/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05950945> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-12-30" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/> .